SMMT

Summit Therapeutics Inc. [SMMT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SMMT Stock Summary

Top 10 Correlated ETFs

SMMT

Top 10 Correlated Stocks

SMMT

In the News

SMMT Financial details

Company Rating
-
Market Cap
2.57B
Income
-1.65B
Revenue
235K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
105
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.31
Forward P/E
-
PEG
-0.01
P/S
9059.74
P/B
21.48
P/C
-
P/FCF
-41.67
Quick Ratio
1.76
Current Ratio
1.8
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.28
EPS next Y
-
EPS next Q
-
EPS this Y
160.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
39.12%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
70.82%
-
-
-
-
SMA20
35%
SMA50
28.57%
SMA100
50%
Inst Own
-
Inst Trans
-
ROA
-747%
ROE
-1363%
ROC
4.47%
Gross Margin
100%
Oper. Margin
198754%
Profit Margin
-692830%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.3-5.22
52W High
+382.1%
52W Low
+2310.5%
RSI
52
Rel Volume
1.45
Avg Volume
2.42M
Volume
3.52M
Perf Week
-11.86%
Perf Month
19.87%
Perf Quarter
18.22%
Perf Half Y
8.39%
-
-
-
-
Beta
-1.197
-
-
Volatility
5.14%, 4.37%
Prev Close
2.05%
Price
24.105
Change
1.13%

Something similar

Top by Market Cap
AVGO
V
APC.DE
META
CMC.DE
Top Correlated ETFs
INCO
DZZ
HYXU
FXB
DWX
Top Correlated Stocks
BNTX
000510.SZ
600303.SS
WPK.TO
PSMT
Similar Market Cap
CRVL
CTRE
0ROG.L
GILPX
SPHY

Company Profile

Healthcare Biotechnology
  • Volume Average 2.42M
  • Market Capitalization 2.57B
  • Employee 105
  • CEO Mr. Robert W. Duggan
  • Headquarters Cambridge,MA,US
  • IPO Date 2015-03-05
  • Website https://www.summittxinc.com

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.